Clinical Trial Update: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Pfizer reports completion and posting of results from a Phase 3 trial evaluating the efficacy and safety of Xeljanz (tofacitinib) in adults with moderate-to-sev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2016-06-07